Digital Look

Welcome to Digital Look++,
you are not logged in

Evgen Pharma (EVG)

Pharma and Biotech

1.64p

Select chart: EPS | Dividend | Revenue

Period Ending	Period	Revenue (£m)	Pre-tax (£m)	EPS	Dividend
30-Sep-23	Interim	0.40	(1.46)	(0.53)p	n/a

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Mar-19	n/a	(3.12)	(2.70)p	n/a	n/a	n/a	n/a	0.0%
31-Mar-20	n/a	(3.17)	(2.07)p	n/a	n/a	n/a	n/a	0.0%
31-Mar-21	0.19	(3.21)	(1.82)p	n/a	n/a	n/a	n/a	0.0%
31-Mar-22	n/a	(3.17)	(0.99)p	n/a	n/a	n/a	n/a	0.0%
31-Mar-23	0.44	(5.01)	(1.47)p	n/a	n/a	n/a	n/a	0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Mar-24	0.40	(4.10)	(1.20)p	n/a	n/a	n/a	n/a	0.0%

	5 Yr High	5 Yr Low	5 Yr Avg	Curr / Avg
Latest	n/a	n/a	n/a	0

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

Find out about IFRS and how this affects the financial infomation for all UK companies.